Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.

Ischemic Stroke

Ginkgolides Meglumine Injection

The first affiliated hospital with Nanjing Medical University

Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.

Blood will be drawn from adult subjects pre-drug application and at 30min, 60min, 90min, 150min, 197min, 205min, 215min, 240min (4h), 300min(5h), 360min (6h), 480min (8h）， 720min (12h)，1440min(24h)，2160min(36h)， 2880min (48h)， 4320min (72h). Urine will be drawn from adult subjects pre-drug application and at 0-4, 4-6, 6-12, 12-24, 24-48, 48-72.

Biological sample including blood, urine, faeces for PK will be collected at the same time point.

Adverse event reports will be assessed at 0, 4 days. Vital sign measurements will be assessed at pre-drug application and 30min, 60mi, 120min, 197min, 4h, 12h, 24h, 48h, 72h after application. Electrocardiogram will be assessed at 0, 4 days. Electrocardiogram monitoring will be assessed during medication period. Clinical laboratory tests will be assessed at 0, 4 days.

Jiangsu Kanion Pharmaceutical Co., Ltd

Beijing Bionovo Medicine Development Co., Ltd.

Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.

25mg, intravenous drip, once a day. Number of Cycles: 14 days.

CN051

CN071

CN072

CN073

CN027

CN054

CN001

CN083

CN050

CN080

CN041

CN043

CN029

CN079

CN007

CN044

CN018

CN063

CN045

CN059

CN046

CN076

CN078

CN035

CN036

CN024

CN025

CN042

CN052

CN002

CN070

CN084

CN077

CN026

CN069

CN085

CN040

CN062

CN022

CN058

CN030

CN021

CN057

CN075

CN088

CN014

CN055

CN013

CN087

CN074

CN056

CN060

CN061

CN068

CN003

CN049

CN048

CN008

CN006

CN017

CN005

CN023

CN016

CN028

CN020

CN019

CN034

CN033

CN082

CN032

CN012

CN010

CN031

CN011

CN009

CN064

CN065

CN004

CN066

CN067

CN047

CN038

CN039

CN015

CN081

CN053

A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.

A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.

Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.

Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.

Drug Distribution

Pravastatin

Simvastatin

Children's Mercy Hospital

Statin Distribution

Pharmacokinetics of Pravastatin and Simvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition

Jon Wagner

Children's Mercy Hospital Kansas City

American Heart Association

Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction

Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction

Xience V Stent Group

Endeavor Resolute Group

Total

Sex: Female, Male

Region of Enrollment

defined as a composite of cardiac death, Myocardial infarction not clearly attributable to a nontarget vessel and target lesion revascularization

Device-oriented Composite Outcome

defined as a composite of all-cause mortality, any MI (includes non-target vessel territory) and repeat revascularization (includes all target and non-target vessel)

Stent Thrombosis

Any Bleeding

Overall Study

Dr. Seung-Hwan Lee

Myocardial Infarction

Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute

Everolimus eluting stent

Zotarolimus eluting stent

Yonsei University Wonju College of Medicine; Wonju Severance Christian Hospital

Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction

Comparison of the Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Stent for Coronary Lesions in Acute Myocardial Infarction

lactone/enfarktüs

Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.

A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.

Statin Distribution

Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı